We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Erica Bowton is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2007 — 2008 |
Bowton, Erica A. |
F31Activity Code Description: To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
Dopamine Transporter Coding Variant Ala559val With Adhd
[unreadable] DESCRIPTION (provided by applicant): The long-term goal of this proposal is to examine the molecular basis by which the coding variant Ala559Val (A559V), present in the hDAT gene in children with attention deficit hyperactive disorder (ADHD), contributes to the ADHD phenotype. Since ADHD has been linked to hyperactivity of the dopaminergic system, the hypothesis is that the hDAT coding variant A559V mediates changes in the sensitivity of hDAT for intracellular signals that are involved in reverse transport of DA. These changes may promote a state of DAT that would result in increased dopamine (DA) efflux and, as a consequence, increased extracellular DA levels. Importantly, the single nucleotide polymorphism, A559V, is the first mutation in DAT with an anomalous function to be linked to ADHD. Thus, the mechanism by which A559V produces changes in DA signaling by altering extracellular DA levels may be a potential target for the design of small molecules that could provide a novel approach to the treatment of ADHD. Because ADHD is frequently treated with amphetamine, the proposal will also evaluate how the A559V hDAT is distinct from the wild type hDAT in its response to amphetamine.[unreadable] [unreadable]
|
0.958 |